Our Science

TIL Therapy – How it works

TIL – A NATURAL IMMUNE RESPONSE TO TREAT CANCER

TILs are immune cells that recognize, attack, and kill cancer cells. TILs recognize cancer cells through tumor antigens expressed on the surface of cancer cells that are unique to each person. When cancer grows and metastasize, TILs lose their ability to perform their intended function. Ineffective TILs give the tumor cells a chance to evade the immune system and grow.

HOW TIL & TCR-T THERAPIES WORK

By strengthening the patient’s own immune response cancer can be treated. Investigational treatments have demonstrated complete and durable remission in a range of solid cancer tumors with both TIL- and TCR-T-based therapies (Receptor-modified T-cells). In polyclonal TIL therapy a patient’s naturally occurring TILs are collected through tumor biopsy, grown ex-vivo and then infused back to the patient. T target specific antigens, the T-cell receptor (TCR) can be modified to make them more reactive before expanded ex-vivo from the patient’s own peripheral blood.

CytoPLY^TM Pioneers Next Generation T-cell Immunotherapy

CytoPLY^TM is an advanced T-cell activation and expansion platform that amplifies cytotoxicity, unlocking revolutionary opportunities in T-cell therapy such as polyclonal TIL and monoclonal TCR-T.

Stronger

Produces T-cells with enhanced functionality, through increased persistence and increased cytokine production.

Broader

Preserves and expands diverse TCR repertoires, targeting a wider range of tumor antigens.

Faster

Accelerates T-cell expansion, achieving higher cell numbers in less time compared to conventional expansion protocols based on IL-2 alone.

CuraCell’s first product, CC-38, targets prostate cancer and colorectal cancer

CuraCell’s first generation product is an unmodified polyclonal TIL with amplified cytotoxicity from CytoPLY^TM. A proprietary dosing regime combined with checkpoint inhibition ensures a synergistic and lasting response as well as a more gentle pre-treatment of the patient.

Patient-named treatments of CC-38 show promising results. Complete and partial responses across a diverse group of cold solid tumor patients demonstrate the potency and broad applicability of CC-38. In its first clinical program CC-38 targets late-stage prostate cancer and colorectal cancer with a vast unmet medical need.